Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News BioCryst Pharmaceuticals Inc BCRX

Healthcare Biotechnology
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with complement-mediated and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of... see more

Recent & Breaking News (NDAQ:BCRX)

BioCryst Announces Completion of Patient Enrollment in OPuS-2: a Clinical Trial of Avoralstat in Patients With HAE

GlobeNewswire October 8, 2015

BioCryst Announces Successful Phase 1 Clinical Trial of BCX7353

GlobeNewswire October 8, 2015

Sanj K. Patel Appointed to BioCryst's Board of Directors

GlobeNewswire September 29, 2015

BioCryst Reports Second Quarter 2015 Financial Results

GlobeNewswire August 7, 2015

BioCryst Reports Second Quarter 2015 Financial Results

GlobeNewswire August 7, 2015

Robert Ingram Appointed to BioCryst's Board of Directors

GlobeNewswire August 6, 2015

BioCryst to Announce Second Quarter 2015 Financial Results August 7

GlobeNewswire July 23, 2015

BioCryst to Present at the JMP Securities Life Sciences Conference

GlobeNewswire June 18, 2015

BioCryst Licenses Worldwide Rights to Commercialize RAPIVAB(R) Influenza Treatment to CSL Limited

GlobeNewswire June 17, 2015

BioCryst to Present at the Jefferies 2015 Healthcare Conference

GlobeNewswire May 26, 2015

BioCryst Announces Initiation of a Phase 1 Clinical Trial of BCX7353 for the Treatment of Hereditary Angioedema

GlobeNewswire May 13, 2015

BioCryst Reports First Quarter 2015 Financial Results

GlobeNewswire May 8, 2015

BioCryst to Present at the Bank of America Merrill Lynch 2015 Healthcare Conference

GlobeNewswire May 5, 2015

BioCryst to Announce First Quarter 2015 Financial Results May 8

GlobeNewswire April 23, 2015

BioCryst to Present at the Needham Healthcare Conference

GlobeNewswire April 7, 2015

BioCryst Awarded BCX4430 Advanced Development Contract

GlobeNewswire March 31, 2015

BioCryst to Present at Two Upcoming Investor Conferences

GlobeNewswire February 26, 2015

BioCryst Reports Fourth Quarter & Full Year 2014 Financial Results

GlobeNewswire February 18, 2015

BioCryst to Announce 2014 Financial Results February 18 & Present at the 2015 Leerink Global Healthcare Conference

GlobeNewswire February 5, 2015

FDA Grants Fast Track Designation for BCX4161 for the Treatment of Hereditary Angioedema

GlobeNewswire January 26, 2015